Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Merck Millipore Introduces Parteck® SLC

Published: Wednesday, October 23, 2013
Last Updated: Wednesday, October 23, 2013
Bookmark and Share
Delivers dramatically increased solubility and bioavailability.

Merck Millipore has introduced Parteck® SLC, a new excipient with a unique surface structure that delivers significantly increased loadability for active pharmaceutical ingredients (API).

Featuring a unique pore structure, Parteck® SLC for drug delivery enables loading of oral dosage forms with amorphously distributed API to the highest levels, dramatically increasing API solubility.

"Many promising drug candidates fail during development due to poor bioavailability and represent a significant loss of time and resources invested in drug development," noted Matthias Bucerius, Ph.D., Head of Pharmaceutical Raw Materials.

Bucerius continued, "With the addition of Parteck® SLC to our extensive portfolio of excipients, drug developers now have a new option to help increase solubility and bioavailability and advance drug development. With Parteck® SLC, molecules can also be reformulated, potentially extending the life cycle of the drug."

Parteck® SLC's mesopores (2-7 nm) create a surface area of up to 1000 m2/g for depositing an API in its amorphous form needed for supersaturation. The internal surface area of Parteck® SLC is also easily accessible and the API is always kept stable.

Feasibility studies have proven the superior performance on dissolution of Parteck® SLC both in vitro and in vivo.

A user-friendly particle size (5-25 μm) and bulk density (0,32 g/ml) allow easy loading, tableting, or capsule creation. In conjunction with Parteck® ODT, a directly compressible excipient, Parteck® SLC helps to produce stable and fast acting tablets. The loaded granulate retains its performance during dissolution in solid dosage forms.

As an EMPROVE® product, Parteck® SLC comes with ready-to-use documentation in CTD-format, saving time and money in the registration of the final drug. Feasibility studies concerning loading and in vitro dissolution are also available.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,300+ scientific posters on ePosters
  • More Than 4,900+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Merck Millipore Enters Into Strategic Alliance with Turgut Ilaç
Company to provide Provantage® End-to-End solution for development and manufacture of biosimilars.
Friday, October 23, 2015
Merck Millipore Introduces Enhancements to its EMPROVE® Program
Instant, online access to regulatory and technical information on portfolio of 400 products.
Thursday, September 17, 2015
Merck Millipore Enters Into Agreement with Singulex
Acquiring exclusive worldwide rights to Singulex’s SMC™ technology - instruments, assays and services - for research applications.
Thursday, May 28, 2015
Merck Millipore Announces Agreement with Precision Biologics
Merck Millipore services include design and development of cost-effective process to deliver high yield and productivity.
Thursday, February 05, 2015
Merck Millipore Expands Biomanufacturing Sciences and Training Center in Japan
Facility expansion and relocation of existing operations from Yokohama, Kanagawa Prefecture to Tokyo.
Thursday, August 28, 2014
Merck Millipore Invests €12M in France Facility
The investments will expand ready-to-use media manufacturing at company's Molshiem facility.
Tuesday, August 12, 2014
Princeton’s Dr Bonnie Bassler Receives 2014 Alice C. Evans Award
Merck Millipore congratulates winner of the Alice C. Evans award for leadership in clinical microbiology.
Thursday, May 22, 2014
Merck Millipore Announces Incoming CEO and President
Udit Batra, Ph.D. will be responsible for the organization’s strategic direction to drive growth and product innovation as well as oversight of the worldwide operations.
Tuesday, April 15, 2014
Merck Millipore, VWR Extend Western European Distribution Agreement
Provides VWR access to more Merck Millipore products and reagents for chemical and microbiological analysis.
Wednesday, April 09, 2014
Merck Millipore Introduces the Lab Solutions Virtual Conference: “Complete Solutions for Food Safety Analysis.”
Merck Millipore, the Life Science division of Merck KGaA has announced the first Lab Solutions Virtual Conference on November 19 and 20, 2013.
Tuesday, November 05, 2013
Merck Millipore Announces Co-marketing Agreement with groninger
Offering combines industry-leading single-use assemblies, sterility assurance solutions and stainless steel filling equipment.
Tuesday, August 13, 2013
Merck KGaA Passes EXCiPACT Audit for Certification as Provider of Pharmaceutical Excipients
Ensures current GMP and GDP requirements applied to pharmaceutical excipients through a recognized auditing and certification process.
Friday, August 02, 2013
Merck Millipore Partners with Gyros
Partnership to develop, manufacture and commercialize kits on the Gyrolab™ immunoassay platform.
Tuesday, July 16, 2013
Merck Millipore Opens New R&D Center
Facility fosters company's focus on Bioavailability Enhancement.
Monday, July 15, 2013
Merck Millipore Introduces the Lab Water Virtual Conference
“The Lab of Tomorrow, Bringing the Future to Life Today”.
Wednesday, May 22, 2013
Scientific News
Breakthrough Flu Vaccine Inhibited by Pre-existing Antibodies
Universal truths – how existing antibodies are sabotaging the most promising new human flu vaccines.
Gene Therapy for Metabolic Liver Diseases
Researchers have tested gene therapy in pigs from hereditary tyrosinemia type 1, with corrected liver cells being transplanted into the diseased liver.
Zika Vaccine Candidates Show Promise
Two experimental vaccines have shown promise against a major viral strain responsible for the Brazilian Zika outbreak.
New Medication Shows Promise Against Liver Fibrosis in Animal Studies
Liver fibrosis is a gradual scarring of the liver that puts people at risk for progressive liver disease and liver failure.
Raw Eggs Deemed Safe to Eat
A report published today by the Advisory Committee on the Microbiological Safety of Food (ACMSF) into egg safety has shown a major reduction in the risk from salmonella in UK eggs.
Monitoring TTX Toxin in Shellfish
In a number of small studies, mussels and oysters from the eastern and northern part of the Oosterschelde in Holland were found to contain tetrodotoxin (TTX).
Gene Terapy for Muscle Wasting Developed
New gene therapy could save millions of people suffering from muscle wasting disease.
NIH Begins Yellow Fever Vaccine Trial
NIH has initiated an early-stage clinical trial of a vaccine to protect against yellow fever.
Gene-Editing 'Toolbox' Targets Multiple Genes Simultaneously
Researchers have designed a system that modifies, or edits, multiple genes in a genome at once while minimising unintentional effects.
Detecting Alzheimer's with Smell Test
Odour identification test may offer low-cost alternative for predicting cognitive decline and detecting early-stage Alzheimer’s disease.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,300+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,900+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!